Alton Boynton - Northwest Biotherapeutics Director
| NWBO Stock | USD 0.23 0.01 4.17% |
Director
Dr. Alton L. Boynton, Ph.D. is Chief Scientific Officer, Director of Northwest Biotherapeutics, Inc.Dr. Boynton cofounded our company, has served as our Chief Scientific Officer and a Director since our inception in 1998, was appointed our Chief Operating Officer in August 2001, was appointed President in May 2003, and served as Chief Executive Officer from June 2007 to June 2011. Prior to founding our company, He headed the Molecular Oncology research lab at the Pacific Northwest Research Foundation . He also served as Director of the Department of Molecular Medicine of Northwest Hospital from 1995 to 2003 where he coordinated the establishment of a program centered on carcinogenesis. Prior to joining Northwest Hospital, He was Associate Director of the Cancer Research Center of Hawaii, The University of Hawaii, where he also held the positions of Director of Molecular Oncology of the Cancer Research Center and Professor of Genetics and Molecular Biology. He received his Ph.D. in Radiation Biology from the University of Iowa in 1972. We believe Dr. Boyntons background and experience make him well qualified to serve as a Director. since 2012.
| Age | 78 |
| Tenure | 13 years |
| Professional Marks | Ph.D |
| Phone | 240 497-9024 |
| Web | www.nwbio.com |
Northwest Biotherapeutics Management Efficiency
The company has return on total asset (ROA) of (1.2576) % which means that it has lost $1.2576 on every $100 spent on assets. This is way below average. Northwest Biotherapeutics' management efficiency ratios could be used to measure how well Northwest Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 3 records | DIRECTOR Age | ||
| Peter Young | CEL SCI Corp | 74 | |
| Bruno Baillavoine | CEL SCI Corp | 65 | |
| Robert Watson | CEL SCI Corp | 61 | |
Management Performance
| Return On Asset | -1.26 |
Northwest Biotherapeutics Leadership Team
Elected by the shareholders, the Northwest Biotherapeutics' board of directors comprises two types of representatives: Northwest Biotherapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Northwest. The board's role is to monitor Northwest Biotherapeutics' management team and ensure that shareholders' interests are well served. Northwest Biotherapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Northwest Biotherapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Leslie Goldman, Sr. VP of Bus. Devel. | ||
| Linda JD, CEO, Chairperson | ||
| Alton Boynton, Founder, Chief Scientific Officer, Secretary and Director | ||
| David Innes, VP Relations | ||
| Jean Davis, Chief Officer |
Northwest Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Northwest Biotherapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -1.26 | ||||
| Profit Margin | 52.10 % | ||||
| Operating Margin | (54.95) % | ||||
| Current Valuation | 1.03 B | ||||
| Shares Outstanding | 1.05 B | ||||
| Shares Owned By Insiders | 10.04 % | ||||
| Shares Owned By Institutions | 0.23 % | ||||
| Number Of Shares Shorted | 14.14 M | ||||
| Price To Earning | 58.17 X | ||||
| Price To Sales | 858.96 X |
Other Information on Investing in Northwest OTC Stock
Northwest Biotherapeutics financial ratios help investors to determine whether Northwest OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Northwest with respect to the benefits of owning Northwest Biotherapeutics security.